Clinical Trial

Streamlined One-wire Logistics Optimize Transcatheter Aortic Valve Replacement

Study acronym: SOLO-TAVR
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 5, 2025 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this study is to determine the safety and performance of a new guidewire and pacing system called the Fusion System in treating patients undergoing transcatheter aortic valve replacement (TAVR) or similar procedures. The main questions it aims to answer are: Is the Fusion System safe? Is the Fusion System's clinical performance acceptable? Participants will asked to sign a study consent and report any adverse events experienced until they are discharged from hospital (or a maximum of 2 days following their procedure).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-21.
Trial Details
NCT Number NCT07090811
Lead Sponsor Solo Pace, Inc.
Conditions Aortic Valve Disease
Enrollment 20 participants
Start Date 2025-09
Primary Completion 2026-03 (estimated)
Study Completion 2026-04 (estimated)
Updated on ClinicalTrials.gov 2025-08-05